The evidence that BRD4 positively regulates DNA damage checkpoint activation and DSB repair, implicates that its pharmacological inhibition by BETi may increase sensitivity of cancer cells to DDR or ATR inhibitors defining a possible combination strategy in specific tumor settings. This evidence concerns the gene BRD4 and cancer.